Helena Bragd joins Becton Dickinson to lead newly empowered Nordic business

Helena_Bragd_EuropaWire
OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd has joined global medical technology leader Becton, Dickinson and Company (BD) as General Manager for the Nordic region. Helena brings more than 20 years of pharmaceutical- and med-tech leadership experience to the role, gained with other well-known international players in the medical sector, including ResMed, Novartis, Johnson and Johnson and Eli Lilly.

Ms. Bragd’s appointment coincides with the restructuring of BD’s business to give the Nordic region increased emphasis and independence, to increase the focus on local needs and substantially grow the company’s activities in the fields of diabetes care, infectious disease control, medication management, health screening, healthcare worker safety and other strategic sectors.

Helena comments, “I was most interested to take on this leadership role for BD Nordics, firstly because it is a newly empowered business unit, and secondly because the company has recently made a number of important acquisitions that complement the already strong portfolio. This means that we can offer true end-to-end solutions, especially in protecting patient safety in respect of infection prevention and medication management through the whole clinical and therapeutic process. For instance, healthcare acquired infections, particularly those caused by antimicrobial-resistant (AMR) strains of disease-causing microorganisms, are an escalating problem in the Nordic area. Very important in antibiotic stewardship is the use of rapid screening technologies, for example to differentiate between viruses and bacteria, so that healthcare professionals can quickly identify the most appropriate therapy.

“In addition, we are at the forefront of helping healthcare organisations protect the safety of their employees, such as from exposure to potentially fatal infections, including HIV and hepatitis C, caused by injuries with used needles, by encouraging the adoption of safety devices that incorporate needle protection mechanisms.

“Overall, as a business in the Nordics, we are looking to help people live healthier lives. As a leading player in areas that are particularly relevant in the healthcare systems of all four Nordic countries, we intend to play an increasingly active and strategic role helping healthcare organisations to overcome their operational and clinical challenges and to optimise the effective treatment of patients.”

Ends

For more information, please contact Medica Comms:

BDNordics@medicacomms.com
bd_denmark@medicacomms.com

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com

The Danby Building,
Edmund Halley Road
Oxford
www.bd.com

SOURCE: Becton Dickinson

Comments are closed.